CRISPR
FDA Approves Casgevy for Beta-Thalassemia
The FDA approved the cell-based gene therapy Casgevy for transfusion-dependent beta-thalassemia.
JANUARY 18, 2024
Novel Gene Therapy Slashes LDL in Patients With Hypercholesterolemia
VERVE-101, a novel gene therapy using liquid nanoparticles to edit the PCSK9 gene, reduced LDL cholesterol ...
NOVEMBER 20, 2023
Load more